In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...
The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated colorectal cancer (CRC). The approval is ...
These patients were separated into 3 groups to receive either sotarasib at a 960 mg dose once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg daily plus panitumumab (53 ...
Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...
Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab ...
GlobalData on MSN13d
FDA approves Amgen’s combo therapy for colorectal cancerAmgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug ...
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
2 "LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more effectively than the investigated standard of care. This new option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback